ArticleGene therapy2007
Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis.
Article in Gene therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 58 citations in OpenAlex.
- METCAM/MUC18 is a Biomarker and Therapeutic Target for Prostate Cancer.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer.Journal of hematology & oncology · 2025Review
- Role of adhesion molecules in cancer and targeted therapy.Science China. Life sciences · 2024Review
- Channeling the Natural Properties of Sindbis Alphavirus for Targeted Tumor Therapy.International journal of molecular sciences · 2023Review
- Application of DNA Replicons in Gene Therapy and Vaccine Development.Pharmaceutics · 2023Review
- METCAM Is a Potential Biomarker for Predicting the Malignant Propensity of and as a Therapeutic Target for Prostate Cancer.Biomedicines · 2023Review
- Galectin-3 Is a Natural Binding Ligand of MCAM (CD146, MUC18) in Melanoma Cells and Their Interaction Promotes Melanoma Progression.Biomolecules · 2022Article
- MCAM is associated with metastasis and poor prognosis in osteosarcoma by modulating tumor cell migration.Journal of clinical laboratory analysis · 2022Article
- Middle East respiratory syndrome coronavirus vaccine based on a propagation-defective RNA replicon elicited sterilizing immunity in mice.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Evaluation of a Novel Plasmid for Simultaneous Gene Electrotransfer-Mediated Silencing of CD105 and CD146 in Combination with Irradiation.International journal of molecular sciences · 2021Article
- Plasmid DNA-based Alphavirus Vaccines.Vaccines · 2019Review
- Targeting CD146 in combination with vorinostat for the treatment of ovarian cancer cells.Oncology letters · 2017Article
- Ectopic expression of MCAM/MUC18 increases in vitro motility and invasiveness, but decreases in vivo tumorigenesis and metastasis of a mouse melanoma K1735-9 subline in a syngeneic mouse model.Clinical & experimental metastasis · 2016Article
- Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist.Molecular therapy oncolytics · 2016Article
- Alphaviruses in gene therapy.Viruses · 2015Review
- The multifaceted role of CD146/MCAM in the promotion of melanoma progression.Cancer cell international · 2015Article
- Mcam Silencing With RNA Interference Using Magnetofection has Antitumor Effect in Murine Melanoma.Molecular therapy. Nucleic acids · 2014Article
- Alphavirus-based vaccines.Viruses · 2014Review
- MCAM expression is associated with poor prognosis in non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2014Article
- Enhancement of antitumor immunity using a DNA-based replicon vaccine derived from Semliki Forest virus.PloS one · 2014Article
Corrections and comments
- Erratum issuedWu, G-J [added]
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Melanoma patients with metastases have a very low survival rate and limited treatment options. Therefore, the targeting of melanoma cells when they begin to invade and metastasize would be beneficial. An adhesion molecule that is upregulated at the vertical growth phase is the melanoma cell adhesion molecule (MCAM/MUC18). MUC18 is expressed in late primary and metastatic melanoma with little or no expression on normal melanocytes. We utilized the alphavirus-based DNA plasmid, SINCp, encoding murine MUC18 (SINCp c-muMUC18) for vaccination against B16F10 murine melanoma cells expressing murine MUC18. This vaccine effectively protected mice from lethal challenges with melanoma-expressing murine MUC18 in both primary and metastatic tumor models. Vaccination against MUC18 elicited effective humoral and CD8+ T-cell immune responses against melanoma. We propose that targeting molecules important in tumor invasion may be useful in the design of future strategies for the prevention and treatment of melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.